Specialised Therapeutics expands Incyte partnership to market Opzelura in Australia
Biopharmaceutical firm Specialised Therapeutics extended its commercial agreement with Incyte Biosciences to handle regulatory registration distribution and commercialisation of ruxolitinib cream in Australia
Specialised Therapeutics, an independent biopharmaceutical company, has expanded its collaboration with Incyte Biosciences International to market the topical cream ruxolitinib, known as Opzelura®, in Australia. Ruxolitinib is a novel Janus kinase (JAK) inhibitor used for treating non-segmental vitiligo in adults and children aged 12 and above, as well as mild to moderate atopic dermatitis in non-immunocompromised adults and children aged 2 and above, when standard topical therapies are ineffective.
The Australian partnership, announced on September 21, 2026, involves ST managing regulatory submissions, medical affairs, marketing, and distribution, while Incyte remains responsible for development and manufacturing. ST's CEO, Carlo Montagner, emphasized the significance of this expansion into inflammatory dermatology, noting that atopic dermatitis and vitiligo pose substantial physical and psychosocial burdens for patients.
Incyte's Head of International, Lee Heeson, highlighted the alignment between the two companies' operational capabilities. ST expects to progress regulatory and reimbursement submissions for OPZELURA with Australian healthcare authorities in the near future.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
